Search results
Results from the WOW.Com Content Network
The term "Freshman 15" is an expression commonly used in the United States and Canada to refer to weight gain during a student's first year in college. Although the 15 refers to a 15 lb. (6.8 kg) weight gain, the expression can apply to weight gain in general. In Australia and New Zealand, it is sometimes referred to as "First Year Fatties", [1 ...
A 30-month-long treatment with sertraline for OCD also resulted in no significant weight gain. [77] Although the difference did not reach statistical significance, the average weight gain was lower for fluoxetine (1%) but higher for citalopram, fluvoxamine and paroxetine (2.5%). Of the sertraline group, 4.5% gained a large amount of weight ...
It's sophomore year, and suddenly you're finding that your jeans don't fit like they used to? You're not alone. Although so-called "freshman 15" is an exaggeration, most students gain weight in ...
Editor's note: On Feb. 9, Money College writer Megan Cottrell talked about the "Freshman 15" from the perspective of losing weight and gaining in the wallet. Now it's the guys' turn, as Bill ...
Consider this: If you save $3,000 a year when you're between 20 and 30 years old, put the money into an IRA with a 7% average annualized rate of return and never save again, you'll have $442,000 ...
Desmethylsertraline (DMS), also known as norsertraline, is an active metabolite of the antidepressant drug sertraline.Like sertraline, desmethylsertraline acts as a monoamine reuptake inhibitor, and may be responsible for some of its parent's therapeutic benefits; however, the effects of DMS's main activity of increasing serotonin levels via binding to the serotonin transporter appears to be ...
The weight loss injection tirzepatide helped Melanie Ressa lose weight and overcome food noise, emotional eating, and mental health challenges. Her story, here.
A 2024 study investigating the prevalence of persistent post-treatment genital numbness among sexual and gender minority youth found 13.2% of SSRI users between the ages 15 and 29 reporting the symptom compared to 0.9% who had used other medications.